Cryosurvival of Embryos From Dysmorphic Oocytes

Various morphological abnormalities of human oocytes were reported to detrimentally affect embryo development. We observed development of frozen thawed embryos derived from oocytes with normal or abnormal morphological features to the blastocyst stage. Cytoplasmic abnormalities of the oocytes were found to negatively affect cryosurvival potential of the embryos.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cryopreservation Blastocyst

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

VKV American Hospital

Istanbul, 34365, Turkey (Türkiye)

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Human embryos derived from morphologically normal or abnormal mature oocytes that fertilized normally by microinjection procedure.
Embryos were obtained from couples who refused to freeze their supernumerary embryos after fresh embryo transfer in an assisted reproduction treatment cycle.

Exclusion criteria

Embryos obtained after microinjection to immature oocytes taht were in vitro matured in culture.
Embryos obtained from abnormally fertilized zygotes.

Treatment and study plan

Cryopreservation, thawing and blastocyst culture

Procedure

Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Sponsors and collaborators

Lead sponsor

V.K.V. American Hospital, Istanbul

Other

Registry information

Important dates

First posted: Aug 27, 2007
Registry last updated: Aug 27, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed